Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Retained Earnings (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Retained Earnings data on record, last reported at $1.9 million in Q4 2025.

  • For Q4 2025, Retained Earnings rose 93.67% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $1.9 million, up 93.67%, while the annual FY2025 figure was $1.9 million, 93.67% up from the prior year.
  • Retained Earnings reached $1.9 million in Q4 2025 per CRNX's latest filing, down from $2.2 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $2.2 million in Q3 2025 and bottomed at -$720.6 million in Q1 2024.
  • Average Retained Earnings over 5 years is -$152.6 million, with a median of -$623500.0 recorded in 2021.
  • Peak YoY movement for Retained Earnings: plummeted 170659.06% in 2021, then soared 953.16% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$382000.0 in 2021, then crashed by 114866.75% to -$439.2 million in 2022, then tumbled by 48.85% to -$653.7 million in 2023, then soared by 100.15% to $963000.0 in 2024, then skyrocketed by 93.67% to $1.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $1.9 million in Q4 2025, $2.2 million in Q3 2025, and $1.6 million in Q2 2025.